Novel FLT3 inhibitors for AML

Advances and unanswered questions in AML: novel agents, MRD assessment, and immunotherapyПодробнее

A Phase I trial investigating a novel oral FLT3 inhibitor, BMF-500, in FLT3-mutant AMLПодробнее

A Phase I trial of DSP-5336, a novel menin inhibitor, in the treatment of AMLПодробнее

Developing novel FLT3 inhibitor by Jenna DoranПодробнее

The importance of FLT3 inhibitors in AML and factors to consider when choosing between these agentsПодробнее

Novel treatment combinations for FLT3-mutated AMLПодробнее

Phase I/II study of novel FLT3 inhibitor HM43239 in R/R AMLПодробнее

Horizon scan of novel and upcoming AML therapiesПодробнее

FF-10101-01: a novel FLT3 inhibitor for R/R AMLПодробнее

FLT3 inhibitor maintenance after allo-SCT for AMLПодробнее

Role of FLT3 Inhibitors and Other Novel Agents in AMLПодробнее

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical PathwaysПодробнее

Development of a Novel NGS-Based Assay for MRD in FLT3-ITD AMLПодробнее

An exciting development: FLT3 inhibitors as a combination therapy?Подробнее

Novel potent and selective FLT3 inhibitorsПодробнее

Combining FLT3 and SYK inhibition for AMLПодробнее